Gemtuzumab ozogamicin in combination with intensive chemotherapy in relapsed or refractory acute myeloid leukemia.
In: Leukemia & Lymphoma, Jg. 56 (2015-08-01), Heft 8, S. 2326-2330
academicJournal
Zugriff:
The prognosis of refractory/relapsed acute myeloid leukemia (AML) remains poor. The complete response (CR) rate after relapse is around 25%, with 11% of patients still alive after 5 years. The efficacy and toxicity of fractionated gemtuzumab ozogamicin (fGO; 3 mg/m2, days 1, 4, 7) in combination with intensive chemotherapy were retrospectively evaluated in patients with refractory/relapsed AML. Thirty-six patients (median age 54 years) were included. European LeukemiaNet classification was as follows: favorable (n= 6), intermediate-I (n= 13), intermediate-II (n= 8), adverse (n= 9). Median CR duration was 7.16 months (1.63–96.8). The overall response rate was 38.8%, with CR in eight patients (22.2%) and CR with incomplete platelet recovery (CRp) in six patients (16.7%). Two-year overall survival was 26% (95% confidence interval [CI]: 12–42) and 2-year relapse free-survival was 18.5% (95% CI: 6.6–35.0). Salvage therapy with fractionated GO in patients with very high-risk disease produced a 38.8% response rate and may be considered as a bridge therapy to transplant. [ABSTRACT FROM PUBLISHER]
Copyright of Leukemia & Lymphoma is the property of Taylor & Francis Ltd and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Titel: |
Gemtuzumab ozogamicin in combination with intensive chemotherapy in relapsed or refractory acute myeloid leukemia.
|
---|---|
Autor/in / Beteiligte Person: | Chantepie, Sylvain P. ; Reboursiere, Emilie ; Mear, Jean-Baptiste ; Gac, Anne-Claire ; Salaun, Veronique ; Benabed, Khaled ; Cheze, Stéphane ; Johnsonansah, Hyacinthe ; Macro, Margaret ; Vilque, Jean-Pierre ; Reman, Oumedaly |
Zeitschrift: | Leukemia & Lymphoma, Jg. 56 (2015-08-01), Heft 8, S. 2326-2330 |
Veröffentlichung: | 2015 |
Medientyp: | academicJournal |
ISSN: | 1042-8194 (print) |
DOI: | 10.3109/10428194.2014.986478 |
Schlagwort: |
|
Sonstiges: |
|